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DOI 10.1186/s12974-015-0320-xRESEARCH Open AccessLenalidomide reduces microglial activation and
behavioral deficits in a transgenic model of
Parkinson’s disease
Elvira Valera1, Michael Mante1, Scott Anderson1, Edward Rockenstein1 and Eliezer Masliah1,2*Abstract
Background: Parkinson’s disease (PD) is one of the most common causes of dementia and motor deficits in the
elderly. PD is characterized by the abnormal accumulation of the synaptic protein alpha-synuclein (α-syn) and
degeneration of dopaminergic neurons in substantia nigra, which leads to neurodegeneration and neuroinflammation.
Currently, there are no disease modifying alternatives for PD; however, targeting neuroinflammation might be a viable
option for reducing motor deficits and neurodegeneration. Lenalidomide is a thalidomide derivative designed for
reduced toxicity and increased immunomodulatory properties. Lenalidomide has shown protective effects in
an animal model of amyotrophic lateral sclerosis, and its mechanism of action involves modulation of cytokine
production and inhibition of NF-κB signaling.
Methods: In order to assess the effect of lenalidomide in an animal model of PD, mThy1-α-syn transgenic
mice were treated with lenalidomide or the parent molecule thalidomide at 100 mg/kg for 4 weeks.
Results: Lenalidomide reduced motor behavioral deficits and ameliorated dopaminergic fiber loss in the striatum.
This protective action was accompanied by a reduction in microgliosis both in striatum and hippocampus. Central
expression of pro-inflammatory cytokines was diminished in lenalidomide-treated transgenic animals, together with
reduction in NF-κB activation.
Conclusion: These results support the therapeutic potential of lenalidomide for reducing maladaptive
neuroinflammation in PD and related neuropathologies.
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Disorders with parkinsonism and dementia affect over
ten million people worldwide. Jointly, this heterogeneous
group of disorders is known as Lewy body diseases [1–3]
and includes idiopathic Parkinson’s disease (PD), PD de-
mentia, and dementia with Lewy bodies. Neuropathologi-
cally, these disorders are characterized by accumulation
of protease-resistant alpha-synuclein (α-syn) in synapses
and axons, formation of neuronal inclusions, known as
Lewy bodies, and degeneration of selected neuronal popu-
lations in the neocortex, limbic, and striato-nigral systems,
accompanied with neuroinflammation [4–6]. α-syn is a* Correspondence: emasliah@ucsd.edu
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unless otherwise stated.14 kDa neuronal protein involved in synaptic transmission
and vesicle release [7, 8], and increasing evidence supports
the notion that progressive accumulation of α-syn plays
a central role in the pathogenesis of PD. The mecha-
nisms through which α-syn triggers neurodegeneration
are not completely understood; however, several lines of
investigation support the possibility that formation of toxic
α-syn aggregates might be important [9, 10]. Moreover,
recent studies suggest that under pathological circum-
stances, toxic α-syn aggregates can be secreted [11–13].
These extracellular α-syn aggregates can then transfer
from neuron to neuron [14] or from neuron to glial cells
[15, 16], where they trigger and activate pro-inflammatory
pathways and exacerbate the neurodegenerative process.
In PD and animal models, activated microglia and
astroglia with increased tumor necrosis factor α (TNFα)This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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elevated in microglia [18], and α-syn oligomers activate
microglia promoting the release of TNFα and interleukin
(IL)-6 in a TLR2-dependent manner [18–20]. The down-
stream signaling mechanisms leading to neuroinflamma-
tion are not fully understood, but recent evidence supports
a role for NF-κB activation [21]. Therefore, given the po-
tential toxicity of α-syn aggregates via pro-inflammatory
pathways, therapeutic approaches for PD might involve
both reducing the levels of α-syn and modulating neuroin-
flammatory cascades. Our hypothesis is that compounds
that inhibit NF-κB signaling might attenuate neuroinflam-
mation and degeneration in a α-syn transgenic (tg) model
of PD. In this sense, thalidomide and its derivatives have
been shown to protect in several inflammatory and auto-
immune disorders by inhibiting the production of TNFα
and other pro-inflammatory cytokines [22–24], and by
blocking NF-κB signaling [21].
In this context, we evaluated the efficacy of lenalido-
mide and its parent molecule thalidomide at reducing
neuroinflammation and neuropathology in the mThy1-
α-syn tg model of PD. While lenalidomide did not reduce
α-syn load, it did ameliorate behavioral deficits, dopamin-
ergic fiber loss, and microgliosis. This effect was accom-
panied with diminished expression of TNFα and other
pro-inflammatory cytokines and increased expression of IL-
10, fractalkine, and IL-13, which have anti-inflammatory
properties. These results support the hypothesis that lenali-
domide reduces neuroinflammation and might be of use in
PD and related disorders.
Methods
Animal treatments
Mice expressing human α-syn under the control of the
murine Thy1 promoter (mThy1-α-syn tg) were gener-
ated as previously described [25]. A total of 38 9-month-
old mice were used in this study. The mThy1-α-syn tg
mice and their non-tg littermates were treated for
5 weeks with either vehicle (0.5 % methocellulose), lena-
lidomide, or thalidomide (100 mg/kg). Neither lenalido-
mide nor thalidomide had a significant effect on the
parameters analyzed in non-tg animals, and results are
not shown for the sake of clarity. Vehicle or drugs were
administered via gavage 5 times a week in a 5 ml/kg vol-
ume. Solutions were made fresh weekly. All animal proce-
dures were approved by the UCSD Institutional Animal
Care and Use Committee.
Total activity and round beam test
The behavioral assessment of the animals was performed
using the open field and the round beam tests. As previ-
ously described [26], the total activity test was conducted
for four trials each day for a period of 4 days. Total ac-
tivity was calculated as total beam breaks in 10 min, andthigmotaxis was calculated as the percentage of time
spent in the periphery.
The round beam test allows for the assessment of gait
and balance impairments over a round beam placed
horizontally [26]. Three consecutive trials of 1 min each
were run in 1 day. The total distance traveled forward
and the number of foot slippages were recorded. Speed
on the beam is calculated as ‘distance traveled/time,’ and
errors on the beam are calculated as ‘foot slips/distance
traveled’.
Immunohistochemical analysis
After behavioral analysis, mice were sacrificed under
anesthesia following National Institutes of Health (NIH)
guidelines for the human treatment of animals, and
brains were removed. The right hemibrain was fixed by
immersion in 4 % paraformaldehyde in PBS pH 7.4 and
serially sectioned at 40 μm with a Vibratome apparatus
(Leica) for subsequent analysis. The left hemibrain was
stored at −80 °C for biochemical analysis, and further
processed for either quantitative real-time polymerase
chain reaction (qPCR) or protein analysis.
Vibratome sections were immunolabeled overnight with
antibodies against α-syn (Sigma, 1:250), glial fibrillary
acidic protein (GFAP) (Millipore, 1:500), ionized calcium-
binding adapter molecule 1 (Iba1) (Wako, 1:2000), or
tyrosine hydroxylase (TH) (Millipore, 1:500) followed by
incubation with species-appropriate secondary antibodies
(Vector Laboratories). Sections were reacted with 3,3′-
diaminobenzidine (Vector Laboratories) and imaged on
an Olympus BX41 microscope. A minimum of 100 cells
were counted per animal, and cell counts are expressed as
the average number of positive cells per field (230 μm×
184 μm). Quantification of GFAP, Iba1, and TH staining
was performed by obtaining optical density measurements
using the Image Quant 1.43 program (NIH) and corrected
against background signal levels.
Quantitative real-time PCR analysis
Total RNA was extracted from the mouse anterior hemi-
brain using a Qiagen RNeasy kit and following the instruc-
tions of the manufacturer. RNA (0.5 μg) per sample were
used for reverse transcription to cDNA using a High cap-
acity cDNA reverse transcription kit (Applied Biosystems).
qPCR was performed using TaqMan Fast Advanced
Master Mix and the appropriate TaqMan primers (Life
Technologies). qPCR reactions were run in an StepOnePlus
Real-Time PCR system, and ΔΔCt calculations were made
using StepOne software (Applied Biosystems).
Immunoblot analysis and mouse cytokine array
Protein homogenates were prepared from the mouse pos-
terior hemibrain. Briefly, frozen samples were sonicated in
homogenization buffer (HEPES 1 mM, benzamidine 5 mM,
Fig. 1 Lenalidomide reduces motor behavioral deficits in mThy1-α-syn
tg mice. Non-tg and tg animals treated with either vehicle, lenalidomide,
or thalidomide were analyzed in the open field and round beam tests.
a Total activity, measured as total beam breaks. b Thigmotaxis,
measured as the percentage of time spent in the periphery. c Speed
in the round beam test, measure as decimeters travelled per second.
d Number of slippages (errors) per 10 cm in the round beam test. Error
bars represent ± SEM. *, #p < 0.05; **p < 0.01; ###p < 0.001
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NaN3 0.05 %, protease inhibitor cocktail set III 1:100, phos-
phatase inhibitor cocktail set II 1:100) and ultracentrifuged
at 100,000 rpm for 1 h to obtain cytosolic (soluble) and par-
ticulate (insoluble, membrane bound) fractions. Twenty mi-
crograms of protein from the cytosolic or particulate
fractions were loaded onto 4–12 % Bis-Tris SDS-PAGE
gels (Invitrogen) and transferred onto Immobilon mem-
branes. After overnight incubation with antibodies against
total α-syn (Millipore), NF-κB p65 (Santa Cruz), CX3CL1
(Santa Cruz), or TNFα (Santa Cruz), membranes were
incubated in HRP-linked secondary antibody (American
Qualex), reacted with ECL Western blotting substrate
(Perkin Elmer), and developed in a VersaDoc gel-imaging
machine (BioRad). Immunoblotting images were analyzed
using Quantity One software (BioRad).
The relative levels of 40 different mouse cytokines were
analyzed using a Mouse cytokine panel array (R&D Systems)
in 400 μg of protein from the cytosolic fraction of brain
tissue homogenates (n = 4 per condition), following the
instructions of the supplier.
BV-2 cell culture
The murine microglial cell line BV-2 was cultured as previ-
ously described [27]. For protein extraction and western
blotting, cells were plated onto 12-well plates at a cell
density of 1.15 × 105 cells per cm2. Human α-syn oligomers
were prepared as previously described [28]. For in vitro
treatments, the concentrations used were as follows: hu-
man α-syn aggregates, 5 μM; lenalidomide, 250 μg/ml; and
thalidomide, 250 μg/ml. Controls included vehicle-only-
treated cells and cells treated with Kdo2-Lipid A 100 ng/ml
(Cayman Chemicals) (not shown). For protein analysis,
samples were centrifuged at 5000×g for 5 min to obtain
cytosolic and nuclear fractions. Immunobloting was per-
formed as described above, using antibodies against NF-κB
p65 (C-20, Santa Cruz), TNFα (Santa Cruz), and actin
(Millipore). qPCR analysis was performed following the
same protocol for mouse samples.
Statistical analysis
Differences between groups (n = 5–7) were tested using
Student’s t test or one-way analysis of variance (ANOVA)
with Dunnett’s post hoc test. For in vitro assays, all condi-
tions were assayed in duplicate and repeated in at least two
separated experiments. All results are expressed as mean ±
SEM. The following legends were used for denoting signifi-
cance: *, #p < 0.05; **, ##p < 0.01; ***, ###p < 0.001.
Results
Lenalidomide reduced behavioral deficits and
dopaminergic fiber loss in mThy1-α-syn tg mice
In this study, we focused on the mThy1-α-syn tg mouse
model of PD, which expresses α-syn under the controlof the murine Thy1 neuronal promoter and recapitulates
behavioral and neuropathological deficits similar to those
observed in PD [25]. The animals were treated with either
vehicle, lenalidomide, or thalidomide. We used thalido-
mide for comparison purposes because it is the parent
molecule of lenalidomide and, although it penetrates bet-
ter the blood–brain barrier (BBB) [29, 30], it has lower
anti-TNFα potency than lenalidomide [31, 32]. We mea-
sured total activity and performed motor behavior assess-
ment using the round beam test (Fig. 1). The tg animals
showed an increase in activity and motor errors, as previ-
ously reported for this tg model [33, 34]. Lenalidomide,
but not thalidomide, reduced total activity, increased
speed, and reduced the number of errors in the round
beam test (Fig. 1). These results suggest that lenalidomide
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an ability not shared with its parent molecule thalidomide.
In PD, the parkinsonian features have been correlated
to the loss of dopaminergic input to the striatum [35].
Similarly, in mThy1-α-syn tg mice, there is a reported
loss of TH immunoreactive fibers in the striatum when
compared to the non-tg mice (Fig. 2a, b) [33, 34]. Lenali-
domide and thalidomide both restored TH immunore-
activity in the striatum of the mThy1-α-syn tg mice
to levels similar to non-tg mice. Furthermore, the
mThy1-α-syn tg mice show α-syn accumulation in neur-
onal bodies and neuropil of striatum, hippocampus
(Fig. 2c–f ), and other brain regions (not shown). Immu-
nohistochemical analysis revealed that lenalidomide and
thalidomide had no effect on α-syn accumulation in
the mThy1-α-syn tg mice. Therefore, these results sug-
gest that the behavioral improvement observed with
lenalidomide is not a consequence of reduced α-syn
accumulation.Fig. 2 Lenalidomide reduces dopaminergic fiber loss in the striatum of mT
mThy1-α-syn tg mice treated with vehicle, lenalidomide, or thalidomide. b
immunostaining of the striatum of non-tg and mThy1-α-syn tg mice treate
area positive for α-syn in the striatum. e α-syn immunostaining of the hipp
lenalidomide, or thalidomide. f Percentage of neuropil area positive for α-s
##p < 0.01; ***p < 0.001. Scale bar = 50 μmLenalidomide reduced microgliosis in the mThy1-α-syn tg
mice
Next, we analyzed glial inflammatory responses by im-
munostaining against the glial markers GFAP (astro-
cytes) and Iba1 (microglia) (Fig. 3). The tg mice showed
glial reactivity in hippocampus and other brain areas when
compared with non-tg controls [33], observed as an incre-
ment in cell projections and intensity of the staining.
However, although there was an increase in microglial re-
activity in the striatum of tg animals (Fig. 3b), the differ-
ence with non-tg animals was not statistically significant
at this age. Treatment with lenalidomide or thalidomide
did not affect GFAP staining. However, treatment with
lenalidomide, but not thalidomide, reduced Iba1 immuno-
reactivity both in hippocampus and striatum (Fig. 3b, d).
This amelioration of microgliosis was not observed in
other brain areas (not shown). These results suggest that
lenalidomide is more effective that thalidomide at redu-
cing microglial activation.hy1-α-syn tg mice. a TH immunostaining of the striatum of non-tg and
Optical density quantification of TH staining in the striatum. c α-syn
d with vehicle, lenalidomide, or thalidomide. d Percentage of neuropil
ocampus of non-tg and mThy1-α-syn tg mice treated with vehicle,
yn in the hippocampus. Error bars represent ± SEM. *, #p < 0.05;
Fig. 3 Lenalidomide reduces microgliosis in mThy1-α-syn tg mice. a Iba1 immunostaining of the striatum of non-tg and mThy1-α-syn tg mice
treated with vehicle, lenalidomide, or thalidomide. b Optical density quantification of Iba1 staining in the striatum. c Iba1 immunostaining of the
hippocampus of non-tg and mThy1-α-syn tg mice treated with vehicle, lenalidomide, or thalidomide. d Optical density quantification of Iba1
staining in the hippocampus. e GFAP immunostaining of the striatum of non-tg and mThy1-α-syn tg mice treated with vehicle, lenalidomide,
or thalidomide. f Optical density quantification of GFAP staining in the striatum. g GFAP immunostaining of the hippocampus of non-tg and
mThy1-α-syn tg mice treated with vehicle, lenalidomide, or thalidomide. h Optical density quantification of GFAP staining in the hippocampus.
Error bars represent ± SEM. *, #p < 0.05; ***p < 0.001. Scale bar = 50 μm
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activation in the mThy1-α-syn tg mice
Lenalidomide and thalidomide reportedly reduce the ex-
pression of levels of pro-inflammatory cytokines, such as
TNFα, interferon γ (IFNγ), IL-1β, and IL-6 in peripheral
blood mononuclear cells [24]. Therefore, the mice were
analyzed for the expression of the most relevant pro-
inflammatory and anti-inflammatory cytokines by qPCR
(Fig. 4). The mThy1-α-syn tg mice showed a significant
increase in TNFα mRNA levels, and both lenalidomide
and thalidomide reduced TNFα expression (Fig. 4a). Lena-
lidomide and thalidomide also reduced IL-6, IL-1β, and
IFNγ expression (Fig. 4b–d). Interestingly, lenalidomide
also increased the expression of the anti-inflammatory
cytokine IL-10, while thalidomide did not (Fig. 4e). These
results suggest that lenalidomide might have better anti-inflammatory properties than thalidomide in the tg mouse
brain.
Immunoblot analysis of α-syn levels in cytosolic and
particulate (membrane) fractions revealed that treatment
with lenalidomide or thalidomide did not modify α-syn
levels (Fig. 5a–c). NF-κB activation, measured as the ra-
tio between nuclear and cytosolic fractions, showed that
lenalidomide significantly inhibited NF-κB signaling
(Fig. 5d), which is consistent with its proposed mechan-
ism of action. TNFα protein levels were not significantly
elevated in tg animals when compared to non-tg controls,
but both drugs were able to reduce basal TNFα levels
(Fig. 5e). Finally, CX3CL1 (fractalkine) levels were reduced
in the tg mice and increased in the lenalidomide-treated
mice (Fig. 5f). Fractalkine has been proposed to mediate
neuron-microglial communication in the central nervous
Fig. 4 Lenalidomide modulates cytokine mRNA levels in mThy1-α-syn tg mice. The expression of relevant cytokines was measured by qPCR in
non-tg and mThy1-α-syn tg mice treated with vehicle, lenalidomide, or thalidomide. a TNFα. b IL-6. c IL-1β. d IFN-γ. e IL-10. Error bars represent
± SEM. *, #p < 0.05; ##p < 0.01; ***, ###p < 0.001
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rons and its receptor is expressed by microglia [36, 37].
Fractalkine expression is regulated by NF-κB [38], and it is
involved in microglial activity with neuroprotective prop-
erties [39], further supporting the idea that lenalidomide
has anti-inflammatory effects in vivo.
Immunoblot results were complemented utilizing a
protein array that measures the relative changes of 40
cytokines and chemokines (Fig. 6 and Additional file 1).
Using this array we identified IP-10/CXCL10, JE/CCL2,
and TIMP-1 as pro-inflammatory cytokines that were
significantly dysregulated in the tg mice and which levels
were partially or totally restored after lenalidomide treat-
ment. Moreover, levels of the anti-inflammatory cytokine
IL-13 were elevated after lenalidomide treatment. These
results confirm the anti-inflammatory properties of lena-
lidomide in this tg mouse model.
Lenalidomide regulated microglial NF-κB activation and
TNFα levels in vitro
In order to confirm the results obtained in vivo in the
mThy1-α-syn tg mice, and to further investigate theeffects of lenalidomide in microglial cells, we used the
mouse microglial cell line BV-2 [27]. BV-2 cells were
first incubated with recombinant oligomeric α-syn 5 μM in
a time course analysis for 1, 2, and 3 days, and the activa-
tion of NF-κB and intracellular TNFα levels were mea-
sured by immunoblot (Fig. 7a–d). The expression of TNFα
was further analyzed by qPCR. After 3 days of treatment,
NF-κB activation, measured as the NF-κB p65 nucleus/
cytosol ratio, was significantly induced by the treatment.
The levels of TNFα mRNA decreased after 1–2 days
of treatment with α-syn; however, after that initial re-
duction, TNFα mRNA levels raised significantly above
control levels after 3 days of treatment. Interestingly,
intracellular TNFα levels significantly decreased after
2 days of incubation, probably as a consequence of its
release to the extracellular medium, due to different turn-
over or transduction/translation rates, or a combination of
those factors.
Next, BV-2 cells were treated with α-syn 5 μM plus
lenalidomide or thalidomide at 250 μg/ml for 3 days
(Fig. 7e–h). Lenalidomide inhibited NF-κB translocation
to the nucleus and normalized TNFα mRNA (p < 0.001)
Fig. 5 Lenalidomide modulates NF-κB signaling and cytokine expression in mThy1-α-syn tg mice. a Immunoblot analysis of α-syn, NF-κB p65,
TNFα, and CX3CL1 (fractalkine) in protein extracts from non-tg and mThy1-α-syn tg mice treated with vehicle, lenalidomide, or thalidomide.
Significant results of three to four mice per group are shown. b Densitometric analysis of the levels of the α-syn immunoreactive band in
cytosol, normalized by actin levels. c Densitometric analysis of the levels of the α-syn immunoreactive band in the particulate/membrane
fraction, normalized by actin levels. d Densitometric analysis of the levels of the NF-κB p65 immunoreactive band, expressed as the ratio
between the nuclear and cytosolic fractions. e Densitometric analysis of the levels of the TNFα immunoreactive band in cytosol, normalized by
actin levels. f Densitometric analysis of the levels of the fractalkine immunoreactive band in cytosol, normalized by actin levels. Error bars represent ±
SEM. *, #p < 0.05; ##p < 0.01; ***p < 0.001
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Thalidomide did inhibit NF-κB translocation (albeit not
significantly) and reduced TNFα mRNA levels (p < 0.05)
but had no effect on the intracellular levels of this pro-
tein. These results confirm that lenalidomide is more
potent than thalidomide at reducing TNFα expression in
microglial cells and suggest that this increased potency
may account for some of the differences observed be-
tween both molecules in vitro and in vivo.
In summary, our results suggest that lenalidomide is
more effective than thalidomide at reducing neuroinflam-
mation in the mThy1-α-syn tg model of PD. Furthermore,
lenalidomide or similar thalidomide derivatives might be
of use for ameliorating maladaptive neuroinflammation in
PD and other synucleinopathies.
Discussion
In this manuscript, we investigate the ability of lenalido-
mide at reducing neuroinflammatory responses in a tg
mouse model of PD. Lenalidomide ameliorated motor be-
havioral deficits, protected from dopaminergic fiber loss,
reduced pro-inflammatory cytokine levels, and inhibitedNF-κB activation in vivo and in vitro. Its parent molecule
thalidomide, used for comparative purposes, normalized
some but not all of these parameters. Our results suggest
that lenalidomide or related immunomodulatory drugs
might be good candidates for reducing neuroinflammation
in PD or related synucleinopathies.
Recent studies support the notion that inflammation
plays an important role in the pathogenesis of PD [40].
The mechanisms are not completely understood; however,
factors triggering inflammation may include dysregula-
tion of inflammatory pathways, pathogens, environmental
toxins, and α-syn aggregates [40]. We have recently shown
that aggregated toxic α-syn released from affected neurons
can transmit to other neurons and glial cells [15, 41], lead-
ing to activation of TLR-dependent pathways in microglia
and astrocytes. It has been suggested that activation of
TLRs might lead to NF-κB translocation to the nucleus
and expression of pro-inflammatory genes [42], and evi-
dence supports a role for signaling downstream of TLRs
in PD [43, 19, 44, 45]. Therefore, in addition to its direct
toxic effects in neurons, α-syn could induce neurodegen-
eration by dysregulating pro-inflammatory pathways.
Fig. 6 Lenalidomide modulates pro-inflammatory and anti-inflammatory
cytokine protein levels in mThy1-α-syn tg mice. Additional cytokine
levels were analyzed using a proteomic array in the cytosolic fraction
of non-tg or mThy1-α-syn tg mice treated with vehicle, lenalidomide,
or thalidomide. Significant results are expressed as relative optical density
relative to the non-tg vehicle condition. a IP-10/CXCL10. b JE/CCL2.
c TIMP-1. d IL-13. Error bars represent ± SEM. #p < 0.05; **, ##p < 0.01;
***, ###p < 0.001
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sponses might play a beneficial role in clearing moderate
levels of extracellular α-syn, an over-activation of these
responses (maladaptive inflammation) could result in
neurodegeneration [46]. Supporting a role for maladaptive
inflammation in PD, epidemiological studies have shown
that ibuprofen use is associated with decreased PD risk
[47, 48], and anti-inflammatories reduce degeneration of
dopaminergic neurons in models of PD [49]. Moreover, in
PD and animal models, activated microglia and astroglia
with increased TNFα have been described [17].
The mThy1-α-syn tg mouse model [50] displays micro-
gliosis, astrogliosis, and dysregulation of pro-inflammatory
pathways with TLR activation [18]. As neuroinflammatorycascades triggered by α-syn aggregates might involve
NF-κB activation [51, 52], it follows that targeting this
pathway might be of therapeutic value. Here, we show
that the immunomodulatory drug lenalidomide attenuates
the pathology in a α-syn tg model of PD. Lenalidomide is
a small thalidomide derivative with anti-angiogenic and
immunomodulatory activity that has shown therapeutic
effects in multiple myeloma [53–55] and in animal models
of amyotrophic lateral sclerosis [56, 57]. Its mechanisms
of action involve T cell co-stimulation [58–60], increased
NK cell proliferation and function [58, 60], and inhibition
of the production of TNFα [61, 55, 60], IL-1β, IL-6, IL-12,
and IFNγ [24]. At the molecular level, lenalidomide has
been shown to inhibit NF-κB signaling [21], as confirmed
by our results. Interestingly, lenalidomide compensates for
lower BBB penetration by displaying higher anti-TNFα
and anti-inflammatory potency than thalidomide [29, 30,
62, 31, 32]. Our results support this observation; however,
more in-depth studies of BBB penetration should be per-
formed in the future. Interestingly, TNFα protein levels
were not significantly elevated in tg animals when com-
pared to non-tg controls, suggesting a higher rate of
mRNA transcription compared to protein translation and/
or different turnover rate. However, we cannot rule out
the possibility of local and/or cell-specific changes in
TNFα protein levels that may be functionally relevant. Fi-
nally, regarding the different anti-inflammatory properties
observed between lenalidomide and thalidomide, it can
also be suggested that different cell types and/or brain
regions may be more sensitive to lenalidomide than to
thalidomide, and we cannot rule out the possibility that
thalidomide may exert additional detrimental effects that
could lower its global anti-inflammatory properties com-
pared to lenalidomide. Indeed, the use of derivatives such
as lenalidomide might circumvent the potential secondary
effects of thalidomide [63, 64]. Nevertheless, to take full
advantage of the therapeutic potential of lenalidomide, a
risk assessment for neurotoxicity would be recommended
on a case-by-case basis.
Our results show that lenalidomide improved behavioral
deficits in the mThy1-α-syn tg mice. This improvement
was associated to reduced dopaminergic fiber loss and
reduced microgliosis. The observation that lenalidomide is
more effective at improving behavioral deficits than thal-
idomide may be related to the fact that it reduces micro-
gliosis and pro-inflammatory cytokine production more
effectively than its parent molecule, parameters that are
usually associated with more severe behavioral deficits in
tg models of PD. Interestingly, the effect of lenalidomide
was specific to microglial cells and it did not affect astro-
gliosis. Differences in cell-specific expression profiles of
pro-inflammatory cytokines might be an explanation for
this observation. In this sense, it is also important to note
that lenalidomide acts as a potent immunomodulator in
Fig. 7 Lenalidomide inhibits NF-κB signaling and normalizes TNFα mRNA and protein levels in α-syn-treated microglial cells in vitro. a Microglial
BV-2 cells were challenged with oligomeric recombinant human α-syn 5 μM for 1, 2, or 3 days, and protein extracts analyzed by immunoblot.
Significant results of two independent samples per condition are shown. b Densitometric analysis of the levels of the NF-κB p65 immunoreactive
band, expressed as the ratio between the nuclear and cytosolic fractions after the time course with α-syn. c qPCR analysis of the levels of TNFα
mRNA after the time course with α-syn. d Densitometric analysis of the levels of the cytosolic TNFα immunoreactive band after the time course
with α-syn. e BV-2 cells were challenged with oligomeric recombinant human α-syn 5 μM± lenalidomide or thalidomide 250 μg/ml for 3 days,
and protein extracts analyzed by immunoblot. Significant results of two independent samples per condition are shown. f Densitometric analysis
of the levels of the NF-κB p65 immunoreactive band, expressed as the ratio between the nuclear and cytosolic fractions after 3 days of treatment.
g qPCR analysis of the levels of TNFα mRNA after 3 days of treatment. h Densitometric analysis of the levels of the cytosolic TNFα immunoreactive
band after 3 days of treatment. Error bars represent ± SEM. *, #p < 0.05
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that lenalidomide inhibits NF-κB signaling and normalizes
TNFα mRNA and protein levels in a microglial cell line.
Nevertheless, in order to accurately identify its target cells
in CNS, a more extensive analysis using different cell types
will be necessary.
Lenalidomide also normalized levels of other cytokines
such as fractalkine, IP-10, JE, and TIMP-1. Fractalkine is
constitutively expressed by neurons and is able to reduce
microglial activity by binding to its receptor on glial cells
[39]. In a model of PD, the lack of fractalkine receptor re-
sults in exacerbation of neuronal cell death and increased
production and release of IL-1β by microglia [39]. Levelsof IP-10 correlate with cognitive status in PD patients
[66], and levels of TIMP-1, an endogenous tissue inhibitor
of matrix metalloproteinases, are significantly elevated in
substantia nigra in PD [67]. Finally, it has been observed
that JE levels were upregulated in the striatum and the
ventral midbrain of a model of PD [68]. The fact that lena-
lidomide is able to modulate the expression of these cyto-
kines further confirms its anti-inflammatory activity in the
mThy1-α-syn tg mice.
Conclusions
In conclusion, lenalidomide is able to reduce motor deficits,
dopaminergic fiber loss, microgliosis, and pro-inflammatory
Valera et al. Journal of Neuroinflammation  (2015) 12:93 Page 10 of 11cytokine expression in a tg mouse model of PD. At the
molecular level, lenalidomide inhibits NF-κB activation
and TNFα expression both in vivo and in vitro. These re-
sults suggest that lenalidomide or similar immunomodula-
tory compounds might be of use for the management of
neuroinflammation in PD and related disorders.
Additional file
Additional file 1: Changes in cytokine and chemokine levels in a
transgenic model of PD. Cytokine levels in the cytosolic fraction of
mThy1-α-syn transgenic mice treated with vehicle, lenalidomide, or
thalidomide were analyzed using a proteomic array. Results indicate
the percentage of increase (+) or decrease (−) of the signal with
respect to non-tg control values. *p < 0.05; **p < 0.01; ***p < 0.001.
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